Citigroup Reaffirms “Neutral” Rating for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ:FOLD)‘s stock had its “neutral” rating reiterated by research analysts at Citigroup in a report released on Monday,Benzinga reports. They presently have a $14.50 price target on the biopharmaceutical company’s stock, down from their previous price target of $17.00. Citigroup’s target price would suggest a potential upside of 2.04% from the company’s current price.

Other equities analysts have also recently issued research reports about the company. Wall Street Zen upgraded Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Needham & Company LLC downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 19th. Cantor Fitzgerald cut shares of Amicus Therapeutics from an “overweight” rating to a “hold” rating and lowered their price target for the stock from $21.00 to $14.50 in a report on Friday, December 19th. The Goldman Sachs Group raised their price objective on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amicus Therapeutics in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Amicus Therapeutics has a consensus rating of “Hold” and an average target price of $15.81.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD opened at $14.21 on Monday. Amicus Therapeutics has a 52 week low of $5.51 and a 52 week high of $14.36. The company has a fifty day simple moving average of $9.72 and a two-hundred day simple moving average of $7.96. The company has a quick ratio of 2.09, a current ratio of 2.99 and a debt-to-equity ratio of 1.70. The company has a market cap of $4.38 billion, a price-to-earnings ratio of -355.16 and a beta of 0.46.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.The firm had revenue of $169.06 million during the quarter, compared to analyst estimates of $165.24 million. During the same period last year, the business posted $0.10 earnings per share. Amicus Therapeutics’s revenue was up 19.5% compared to the same quarter last year. As a group, equities analysts anticipate that Amicus Therapeutics will post 0.15 earnings per share for the current fiscal year.

Insider Activity at Amicus Therapeutics

In related news, insider Ellen Rosenberg sold 36,000 shares of the stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $10.00, for a total value of $360,000.00. Following the transaction, the insider directly owned 507,710 shares of the company’s stock, valued at $5,077,100. This trade represents a 6.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Bradley L. Campbell sold 77,926 shares of Amicus Therapeutics stock in a transaction on Monday, December 15th. The stock was sold at an average price of $10.86, for a total transaction of $846,276.36. Following the sale, the chief executive officer owned 1,129,782 shares in the company, valued at $12,269,432.52. This represents a 6.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 345,450 shares of company stock worth $3,657,000. Corporate insiders own 2.20% of the company’s stock.

Institutional Trading of Amicus Therapeutics

Large investors have recently made changes to their positions in the company. Osaic Holdings Inc. grew its stake in Amicus Therapeutics by 450.1% during the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 3,358 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Amicus Therapeutics by 472.6% in the second quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 3,677 shares during the period. Strs Ohio purchased a new position in shares of Amicus Therapeutics during the first quarter worth approximately $30,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Amicus Therapeutics during the third quarter worth approximately $31,000. Finally, Allworth Financial LP increased its holdings in shares of Amicus Therapeutics by 36.3% in the 3rd quarter. Allworth Financial LP now owns 4,678 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 1,246 shares during the period.

More Amicus Therapeutics News

Here are the key news stories impacting Amicus Therapeutics this week:

• Positive Sentiment: Report that BioMarin agreed to acquire Amicus for roughly $4.8 billion — this is a direct, highly constructive development for shareholders because an acquisition at a premium would likely push FOLD materially higher. A $4.8 Billion Reason to Buy BioMarin Stock Today
• Positive Sentiment: Technical/market-interest signal: Amicus cleared a key benchmark and hit a 90-plus relative strength (RS) rating — a sign of strong recent price performance and institutional interest that can support further inflows. Amicus Therapeutics clears key benchmark, hitting 90-plus RS rating
• Neutral Sentiment: Citigroup has a neutral rating on FOLD with a $14.50 price target (down from $17.00) — this trims upside in broker guidance but is not an outright sell signal. Benzinga coverage
• Negative Sentiment: Citigroup downgraded Amicus from “strong-buy” to “hold” — an influential shop trimming its view can weigh on momentum and sentiment. Citigroup downgrades Amicus Therapeutics (FOLD)
• Negative Sentiment: TD Cowen cut its rating from buy to hold and set a $14.50 target — another downgrade that reduces broker-driven buying pressure. Finviz / TD Cowen note
• Negative Sentiment: Insider selling: director David Michael Clark sold 25,642 shares at about $14.17 (disclosed in an SEC filing) — insider sales can be interpreted by some investors as a signal of reduced insider conviction or portfolio rebalancing, which may add short-term selling pressure. SEC filing – insider sale

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.